Figure 1.
Cytopenias and clonal hematopoiesis in patients with relapsed/refractory CLL treated with venetoclax. (A) Kaplan-Meier curve of cumulative incidence of therapy-associated myeloid neoplasm (t-MN) (solid line) across a cohort of 89 patients. The dashed line represents competing risks of death and allo-SCT. The numbers at risk for a given time point refer to at-risk for developing t-MN. (B) Categorization of a cohort of 89 patients into clonal hematopoiesis (CH), idiopathic cytopenias (IC), clonal cytopenias (CC), and t-MNs *CH detected with myeloid disorder-associated gene in 3 cases—not assessed in remaining 18. ^Refers to established myeloid-disorder associated genes, excluding BAX.

Cytopenias and clonal hematopoiesis in patients with relapsed/refractory CLL treated with venetoclax. (A) Kaplan-Meier curve of cumulative incidence of therapy-associated myeloid neoplasm (t-MN) (solid line) across a cohort of 89 patients. The dashed line represents competing risks of death and allo-SCT. The numbers at risk for a given time point refer to at-risk for developing t-MN. (B) Categorization of a cohort of 89 patients into clonal hematopoiesis (CH), idiopathic cytopenias (IC), clonal cytopenias (CC), and t-MNs *CH detected with myeloid disorder-associated gene in 3 cases—not assessed in remaining 18. ^Refers to established myeloid-disorder associated genes, excluding BAX.

Close Modal

or Create an Account

Close Modal
Close Modal